Lpath Addresses Diabetic Neuropathic Pain with Financial Support by NIH

Lpath announced on August 15 the Type 1 Diabetes Preclinical Testing Program of the NIH will provide support for the further study of Lpathomab’s efficacy in animal models of disease, particularly diabetic neuropathy. Lpathomab functions like a ‘molecular sponge’ that binds to, and neutralizes, the bioactive lipid signaling molecule, thus silencing receptors associated with the transmission of pain through the nervous system.  READ MORE

Source: Marketwire

Send this to a friend